Drug Profile
Ensovibep - Molecular Partners
Alternative Names: MP-0420; SKO-136Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Molecular Partners AG
- Developer Molecular Partners AG; Novartis
- Class Antivirals; Proteins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 14 Jul 2023 National Institute of Allergy and Infectious Diseases completes a phase III trial in COVID-2019 infections (Combination therapy) in United Kingdom, Nigeria, Uganda, Singapore, Denmark, Spain, Switzerland, Greece, USA, Poland (IV) (NCT04501978) (EudraCT2020-003278-37)
- 09 Mar 2023 Suspended - Phase-I for COVID-2019 infections (Prevention) in United Kingdom (IV) prior to March 2023 (Molecular Partners AG pipeline, March 2023)
- 09 Mar 2023 Suspended - Phase-I for COVID-2019 infections in United Kingdom (IV) prior to March 2023 (Molecular Partners AG pipeline, March 2023)